PDF hosted at the Radboud Repository of the Radboud University Nijmegen

The following full text is a publisher's version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/80483

Please be advised that this information was generated on 2017-12-30 and may be subject to change.
COX-2 polymorphisms $-765G \rightarrow C$ and $-1195A \rightarrow G$ and colorectal cancer risk


AIM: To determine the possible modulating effect of the COX-2 polymorphisms, $-765G \rightarrow C$ and $-1195A \rightarrow G$, on the risk of colorectal cancer (CRC) in a Dutch population.

METHODS: This case-control study includes 326 patients with CRC and 369 age- and gender-matched controls. Genotypes of the COX-2 polymorphisms $-765G \rightarrow C$ and $-1195A \rightarrow G$ were determined by polymerase chain reaction-based restriction fragment length polymorphism. COX-2 genotypes and haplotypes were analyzed and odds ratios with 95% confidence intervals were estimated by logistic regression.

RESULTS: The $-765GG$ genotype was associated with an increased risk of developing CRC and the $GG/AC$ haplotype seems to protect against CRC. These findings suggest a modulating role for the COX-2 polymorphisms $-765G \rightarrow C$ and $-1195A \rightarrow G$ in the development of CRC in a Dutch population.

© 2009 The WJG Press and Baishideng. All rights reserved.

Key words: Colorectal carcinoma; Cyclooxygenase-2; Genetic polymorphism

INTRODUCTION

Colorectal cancer (CRC) is a common disease in both men and women. CRC includes cancerous growths in the cecum, colon, sigmoid and rectum. In Western countries, 5% of the population ultimately develop CRC, thus this disease is an important public health issue[1]. CRC is ranked the third most common form of cancer worldwide in terms of incidence[2]. In the Netherlands, CRC is the second most common form of cancer affecting women and the third most common form of cancer affecting men. In 2003 in the Netherlands 9898 new cases of CRC were diagnosed[3].

CRC is usually observed in one of three specific patterns: sporadic, inherited or familial. The sporadic form accounts for approximately 70% in the population and is most common in individuals older than 50 years of age, probably as a result of interactions between low penetrance genes and environmental factors. Fewer than 10% of the population has an inherited predisposition to colon cancer. Inherited colon cancer is usually the result of a single germ line mutation. The third pattern, familial colon cancer, includes those families in which CRC development of CRC in a Dutch population.

© 2009 The WJG Press and Baishideng. All rights reserved.
cancer and which are not in a pattern consistent with an inherited syndrome. Up to 25% of all cases of CRC are estimated to fall into this category[1].

Cyclooxygenase (COX), also known as prostaglandin endoperoxidase H synthase, is a modifier gene and key enzyme in the conversion of arachidonic acid into prostaglandins.

The COX family consists of two isozymes: COX-1 and COX-2. COX-1 is constitutively expressed in most cell types and is involved in the homeostasis of various physiological functions. COX-1 is well known as the housekeeping gene. COX-2 is an inducible form and its expression can be induced by mitogenic and proinflammatory stimuli. Increased expression of COX-2 is observed in many types of cancers. COX-2 is also associated with many stages of cancer development, e.g. invasion, metastasis, hyperproliferation, transformation and tumor growth[1,2,3].

Recent studies suggest that single nucleotide polymorphisms (SNPs) in the COX-2 promoter may alter the enzyme function of COX-2 by differential regulation of COX-2 expression. A differential COX-2 expression may influence the risk of the development of gastrointestinal adenocarcinomas, including CRC[4,5].

In a study of African-Americans, an inverse association was found between the Val511Ala polymorphism and the risk of CRC[6]. In two studies the promoter polymorphisms -765G→C and -1195A→G were associated with an increased risk of CRC[7,8], whereas Ulrich et al[9] reported a reduced risk of CRC associated with the -765G→C polymorphism. The inconsistent results may indicate that the COX-2 polymorphisms -765G→C and -1195A→G may play a role in carcinogenic processes in combination with specific life-style conditions or dependent on the racial composition of a particular population.

The purpose of our study was to determine the possible modulating effect of the COX-2 polymorphisms -765G→C and -1195A→G on the risk of sporadic CRC in a Dutch population. The results of this research will lead to a better understanding on the role of SNPs in the COX-2 promoter in colon cancer carcinogenesis. Such knowledge in future may eventually lead to better preventive measures for CRC.

**MATERIALS AND METHODS**

**Patients and controls**

This case-control study included 326 patients with CRC (59.8% men, 40.2% women) and 369 cancer-free controls (59.1% men, 40.9% women). In the patient group, 31.0% had a proximal tumor and 68.1% had a distal tumor, whereas in 0.9% of cases localization of the tumor was unknown (see legend of Table 1). All subjects were of Caucasian origin with a mean age of 63.7 years and were recruited at Radboud University Nijmegen Medical Center, the Netherlands. The patient and control groups were matched for gender and age. The characteristics of patients and controls are summarized in Table 1.

**Genotyping**

DNA from patients and controls was isolated from whole blood using the Pure Gene DNA isolation kit (Gentra Systems, Minneapolis, MN) and stored at 4°C. Genotypes of the COX-2 -765G→C and -1195A→G polymorphisms were determined by polymerase chain reaction (PCR)-based restriction fragment length polymorphism, according to the method of Zhang et al[5].

First, PCR was used to amplify the COX-2 promoter region containing the polymorphism -765G→C and -1195A→G. The primers used to amplify the COX-2 promoter region were 765F5’-TATTAATGGAGATTTAAGCTTG-3’, 765R5’-CCCTTGAGCACTACCCATGAT-3’ and 1195F5’-GCCCTTCATAGGAGATACTGG-3’, 1195R5’-GCCCTTCATAGGAGATACTGG-3’. PCR was performed using a 25 μL reaction mixture containing 100 ng of DNA, 10 mmol/L of Tris/HCl (pH 9.0), 50 mmol/L of KCl, 0.1% of Triton X-100, 2 mmol/L of MgCl2, 200 mmol/L of each primer, 250 μmol/L of deoxyribonucleotide triphosphates and 2.5 U Taq DNA polymerase. The PCR profile for the -1195A→G polymorphism consisted of an initial melting step of 3 min at 95°C, followed by 40 cycles of 30 s at 95°C, 30 s at 58°C, 30 s at 72°C and a final elongation step of 7 min at 72°C. Cycle conditions for the -765G→C polymorphism were 4 min at 95°C, followed by 40 cycles of 30 s at 95°C, 30 s at 54°C, 30 s at 72°C and finally the same elongation step as for the -1195A→G PCR assay. The samples were then analyzed by agarose gel electrophoresis for control of the PCR products.

The PCR products (10 μL) were incubated with 10 U of restriction enzymes Pvu II and Hha I at 37°C for determination of the -1195A→G and -765G→C genotypes, respectively. Finally, the samples were analyzed by agarose gel electrophoresis. The -765G→C and -1195A→G genotypes that could be detected were: 765CC (100 bp fragment), 765GC (100 + 74 + 26 bp fragments), 765GG (74 + 26 bp fragments), 1195AA (273 bp fragment), 1195GA (273 + 220 + 53 bp fragments) and 1195GG (220 + 53 bp fragments), respectively.

**Statistical analysis**

The data analysis was performed using SPSS software.

| Table 1 Characteristics of patients with colorectal cancer (CRC) and controls (mean ± SD) |
|-----------------------------------------------|-----------------------------------------------|
| Patients with CRC | Controls |
| (n = 326) | (n = 369) |
| **Age (yr)** | 62.7 ± 11.7 | 64.5 ± 10.7 |
| Male gender | 195 (59.8%) | 218 (59.1%) |
| Female gender | 131 (40.2%) | 151 (40.9%) |
| Localization of tumor¹ | | |
| Proximal² | 101 (31.0%) | |
| Distal² | 222 (68.1%) | |

¹Note that the localization of the tumor was unknown in 3 patients; ²Proximal tumor: cecum, ascending and transverse colon; Distal tumor: descending colon, sigmoid, rectosigmoid junction and rectum.
(Version 14.0, SPSS, Chicago, IL, USA). Logistic regression was used to assess the association between the genotypes and the risk of CRC. The statistical significance of the -1195A→G and -765G→C genotype distributions between the patient and control groups was determined by Chi-square analysis. A P-value of < 0.05 was used as the criterion of statistical significance and all analyses were adjusted for age and sex. A test for deviation from the Hardy-Weinberg equilibrium, by comparing the expected to observed genotype frequencies, was used. Odds ratios (ORs) and 95% confidence intervals (CI) were calculated. Based on the two polymorphisms tested, a haplotype analysis was performed. In the two populations studied, seven different haplotypes could be distinguished: AC/AC, AG/AC, AG/AG, GC/AC, GG/AC, GG/AG and GG/GG. The localization of the tumor, distal or proximal, was also included in the database analyses.

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Genotype distribution and OR of the COX-2 -1195A→G and -765G→C polymorphisms in patients with CRC and controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genotype</td>
<td>Patients with CRC (n = 326)</td>
</tr>
<tr>
<td>-1195AA</td>
<td>213 (65.3%)</td>
</tr>
<tr>
<td>-1195GA</td>
<td>101 (31.0%)</td>
</tr>
<tr>
<td>-1195GG</td>
<td>12 (3.7%)</td>
</tr>
<tr>
<td>-765GG</td>
<td>241 (73.9%)</td>
</tr>
<tr>
<td>-765GC</td>
<td>79 (23.0%)</td>
</tr>
<tr>
<td>-765CC</td>
<td>8 (2.2%)</td>
</tr>
</tbody>
</table>

OR: Odds ratio; CI: Confidence interval.

<table>
<thead>
<tr>
<th>Table 3</th>
<th>COX-2 haplotypes in patients with CRC and controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haplotype</td>
<td>Patients with CRC (n = 326)</td>
</tr>
<tr>
<td>AC/AC</td>
<td>9 (2.8%)</td>
</tr>
<tr>
<td>AG/AC</td>
<td>59 (18.1%)</td>
</tr>
<tr>
<td>AG/AG</td>
<td>145 (45.4%)</td>
</tr>
<tr>
<td>GC/AC</td>
<td>1 (0.3%)</td>
</tr>
<tr>
<td>GG/AC</td>
<td>16 (4.9%)</td>
</tr>
<tr>
<td>GG/AG</td>
<td>84 (25.8%)</td>
</tr>
<tr>
<td>GG/GG</td>
<td>12 (3.7%)</td>
</tr>
</tbody>
</table>

DISCUSSION

The COX-2 protein was detected in 70% of all colorectal cancer tissues. In adjacent normal colorectal tissue in the same slide the COX-2 protein was not observed. These results suggest that increased expression of COX-2 is associated with CRC. The -765G→C and -1195A→G polymorphisms in the patient group was found with gender and age.

Based on the two polymorphisms tested, a haplotype analysis was performed in the two populations studied and seven haplotypes could be distinguished (Table 3). A significant difference between the COX-2 haplotypes was observed. The GG/AC haplotype was less frequent in patients (OR, 0.44; 95% CI, 0.22-0.85). When the AC, AG and GG haplotypes were investigated separately, the AC haplotype tended to occur less frequently in patients than in controls (OR, 0.78; 95% CI, 0.57-1.06).

We investigated the potential association of the COX-2 polymorphisms -765G→C and -1195A→G and the risk of developing CRC, and found that the -765G→C genotype was present more often in patients than in controls (OR, 1.01 (0.68-1.50)). The -1195A→G polymorphism among patients, was also included in the database analyses.

Next, the potential association of genotype distribution of the two COX-2 polymorphisms with tumor localization was investigated. We distinguished proximal and distal tumor localization. Proximal included the cecum, colon ascendens and colon transversum and distal included the rectum, sigmoid, colon descendens and flexura lienalis. No association between the -765G→C and -1195A→G polymorphisms and tumor localization was detected.

Also no association of the genotype distribution of the -765G→C and -1195A→G polymorphisms in the patient group was found with gender and age.

A study in American Caucasians reported a reduced risk of colorectal adenomas in individuals bearing the -765GG genotype, but this lower risk was found only among users of non-steroidal antiinflammatory drugs (NSAIDs). In addition, a lower risk of adenoma among -765CC genotypes was found only in non-users of NSAIDs. Zhang et al. and Tan et al. reported that the -765GC genotype was associated with an increased risk of CRC.
risk of esophageal squamous cell carcinoma (ESCC) and CRC, in Chinese populations. The findings of Tan et al. and Zhang et al. seem in contrast with our results, since we found a reduced risk of CRC with the -765GC genotype. However, racial differences in the study populations may explain these apparent contradictory results, since the distribution of the COX-2 polymorphisms studied here differs considerably between the Chinese and Dutch study populations. The genotype frequencies found in our Dutch patients with CRC for the -765G→C and -1195A→G polymorphisms were: 73.9% GG, 23.0% GC, 3.1% CC and 65.3% AA, 31.0% GA and 3.7% GG, respectively. Zhang et al. in a Chinese population reported genotype frequencies of 90.6% GG, 9.4% GC, 8.0% CC and 30.5% AA, 52.9% GA and 16.6% GG. Tan et al. in Chinese patients with CRC recently reported approximately the same genotype frequencies as Zhang et al.: 91.6% GG, 8.4% GC, 0.0% CC and 34.5% AA, 49.4% GA and 16.1% GG. These findings suggest that ethnic differences in genotype frequencies of COX-2 polymorphisms may have a significantly different modulating effect on disease phenotypes in different ethnic populations.

According to Zhang et al. and Tan et al. in a Chinese population, the -1195GA and -1195AA genotypes were associated with an increased risk of ESCC and CRC, respectively. This again is not in line with our findings, since we could not demonstrate a significant difference in the allele distribution of the -1195A→G polymorphism between our Dutch patients with CRC and controls.

We also investigated the potential association of the genotype distributions of the -1195A→G and -765G→C polymorphisms with tumor localization. No association between the two polymorphisms and tumor localization was found, which is in accordance with the results of Tan et al. who found a very similar distribution of both COX-2 genotypes in patients with colon (n = 403) or rectal (n = 597) cancer.

The COX-2 GG/AC haplotype (-1195G-765G/-1195A-765C) was found to be present less frequently in patients. When the AC, AG and GG haplotypes were investigated separately, the AC haplotype tended to be less frequently present in patients with CRC than in controls (OR, AG/AC 0.78; 95% CI, 0.57-1.06). This is in line with the findings of Zhang et al., who demonstrated that the luciferase expression of the AG constructs was higher than the expression of the AC constructs, suggesting that the AC haplotype was associated with a lower COX-2 expression and a decreased risk of CRC.

However, Zhang et al., Tan et al. and Moons et al. found an association of the AC haplotype with an increased risk of ESCC, CRC and esophageal adenocarcinoma (EAC). These findings are in contrast with our results, as described above. In addition, the predicted expression levels of the COX-2 protein are higher in AG versus AC haplotype individuals, according to Zhang et al., which is not in agreement with the hypothesis that high expression of COX-2 is a risk factor for colorectal or esophageal carcinoma. It should be noted however that haplotype frequencies of AC are very low in the patient and control populations studied by Zhang et al. and Tan et al., being 4.5% vs 1.6% and 3.8% vs 1.8%, respectively, compared to 21.2% vs 32.6% in our study. In the study of Moons et al., the AC haplotype occurred in 25.0% of the total study population, who were patients with esophageal adenocarcinoma, Barrett’s esophagus and reflux esophagitis, a proportion which is very close to our data. In the study of Moons et al. unfortunately no cancer-free controls were included, but patients with Barrett’s esophagus or reflux esophagitis were used as controls, both of which would confer a risk of esophageal adenocarcinoma.

In summary, we found a significant difference in the -765G→C polymorphism distribution between the patients with CRC and the control group; the -765GG genotype was associated with an increased risk for CRC. The GG/AC haplotype was found less frequently in patients with CRC and may be associated with a reduced risk of CRC. These findings suggest a modulating role for the COX-2 polymorphisms -1195A→G and -765G→C in the development of CRC in a Dutch population.

COMMENTS

Background
Cyclooxygenase-2 (COX-2) is a key enzyme in the development and progression of neoplasms. COX-2 was found to be over-expressed in gastrointestinal tumors, including those of the colon/rectum. The corresponding COX-2 gene is polymorphic and two single nucleotide polymorphisms (SNPs; -1195A→G and -765G→C) were demonstrated to influence the expression of COX-2. Therefore, these polymorphisms may modulate the risk for gastrointestinal cancers, such as cancers of the colon/rectum.

Research frontiers
In this study, the -765GG genotype was associated with an increased risk of developing CRC and the GG/AC haplotype seemed to protect against CRC.

Innovations and breakthroughs
The COX-2 polymorphisms -765G→C and -1195A→G may modulate the development of CRC in a Dutch population.

Applications
Screening for the COX-2 -765GG genotype in a population at risk of colorectal cancer may be valuable in future in order to select the high risk patients. Information and prevention programs can than be focused on these patients.

Terminology
COX-2 is an enzyme that catalyzes the conversion of arachidonic acid in prostaglandin H2, the precursor of other prostaglandins, prostacyclin and thromboxanes. These regulatory compounds play a role in many biological processes such as cell proliferation, angiogenesis, immune function and inflammation, which are all crucial in the development and progression of neoplasms.

Peer review
The manuscript, reported by Hoff et al., analyzes COX-2 polymorphisms -765G→C and -1195A→G and colorectal cancer (CRC) risk in a Dutch population. This manuscript contributes in the effort to characterize some molecular signatures as risk factors for colon cancer in different ethnic populations.

REFERENCES
1 Calvert PM, Frucht H. The genetics of colorectal cancer. Ann Intern Med 2002; 137: 603-612
4 Eisinger AL, Prescott SM, Jones DA, Stafforini DM. The role of cyclooxygenase-2 and prostaglandins in colon cancer.

www.wjgnet.com
Prostaglandins Other Lipid Mediat 2007; 82: 147-154


S- Editor Tian L  L- Editor Cant MR  E- Editor Ma WH